MARKET

RMTI

RMTI

Rockwell Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6531
+0.0151
+2.37%
Closed 19:01 09/24 EDT
OPEN
0.6250
PREV CLOSE
0.6380
HIGH
0.6670
LOW
0.6200
VOLUME
395.69K
TURNOVER
--
52 WEEK HIGH
1.980
52 WEEK LOW
0.5590
MARKET CAP
61.32M
P/E (TTM)
-1.7781
1D
5D
1M
3M
1Y
5Y
Rockwell Medical, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
WIXOM, Mich., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today...
GlobeNewswire · 09/09 13:52
HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $5
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:RMTI) with a Buy and lowers the price target from $5.5 to $5.
Benzinga · 09/07 10:18
--HC Wainwright Adjusts Rockwell Medical's Price Target to $5 from $5.50, Keeps Buy Rating
MT Newswires · 09/07 09:15
Rockwell Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced ...
GlobeNewswire · 08/19 20:00
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Recap: Rockwell Medical Q2 Earnings
Shares of Rockwell Medical (NASDAQ:RMTI) fell 12.6% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 0.00% over the past year to ($0.09), which missed the estimate of ($0.08).
Benzinga · 08/16 20:45
Rockwell Medical Q2 EPS $(0.09) Misses $(0.08) Estimate, Sales $15.14M Miss $18.21M Estimate
Rockwell Medical (NASDAQ:RMTI) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is unchanged from the same period last year. The company
Benzinga · 08/16 20:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RMTI. Analyze the recent business situations of Rockwell Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RMTI stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 131
Institutional Holdings: 20.69M
% Owned: 22.03%
Shares Outstanding: 93.89M
TypeInstitutionsShares
Increased
13
925.46K
New
12
3.21M
Decreased
27
8.68M
Sold Out
24
827.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
John McLaughlin
President/Chief Executive Officer/Director
Russell Ellison
Chief Financial Officer/Executive Vice President
Russell Skibsted
Chief Accounting Officer/Vice President/Controller
Paul McGarry
Vice President - Operations
Michael DeYoung
Other
Marc Hoffman
Other
Raymond Pratt
Independent Director
John Cooper
Independent Director
Allen Nissenson
Independent Director
Robert Radie
Independent Director
Mark Ravich
Independent Director
Andrea Smiley
No Data
  • All
  • Financials
  • Insiders
More
About RMTI
Rockwell Medical, Inc. is a biopharmaceutical company. The Company is targeting end-stage renal disease and chronic kidney disease with products for the treatment of iron deficiency and hemodialysis. The Company is also a manufacturer of hemodialysis concentrates for dialysis providers and distributors. The Company’s renal drug therapy, Triferic, supports disease management initiatives. Triferic is therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. The Company has developed multiple formulations of Triferic: Dialysate Triferic and Intravenous Triferic (I.V. Triferic). Dialysate Triferic is the therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.

Webull offers kinds of Rockwell Medical Inc stock information, including NASDAQ:RMTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RMTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RMTI stock methods without spending real money on the virtual paper trading platform.